Heron Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview

Heron Therapeutics

02/08/2024 21:24

* Heron Therapeutics Inc  HRTX.OQ   HRTX.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 6
for the period ending June 30 2024
    * The San Diego California-based  company is expected to
report a
13.0% increase in revenue to $35.888 million from $31.76 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Heron Therapeutics Inc
is for
a loss of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Heron
Therapeutics Inc is $6.50​, above​ its last closing price
of $2.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.08       -0.09      -0.02     Beat    77.8
 Dec. 31 2024              -0.16      -0.07     Beat    57.2
 Sep. 30 2023              -0.29      -0.17     Beat    ​
 Jun. 30 2023  -0.23       -0.23      -0.35     Missed  -50
 ​​Mar.        -0.21       -0.20      -0.27     Missed  -33
 31 2023                                                
 Jan. 1 0001   -0.30       -0.28      -0.38     Missed  40.4​
 Sep. 30 2022  -0.38       -0.38      -0.38     Met     -1.1
 Jun. 30 2022  -0.53       -0.50      -0.55     Missed  -8.9
 This summary was machine generated August 2 at 20:24 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)